17.77

3.32% -0.61

Amylyx Pharmaceuticals Inc (AMLX)

Overview News Price History Option Chain Financials Discussions Forecast

Amylyx Pharmaceuticals Inc stock is traded at $17.77, with a volume of 1.07M. It is down -3.32% in the last 24 hours and up +32.02% over the past month. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Previous Close:

$18.38

Open:

$18.335

24h Volume:

1.07M

Relative Volume:

0.81

Market Cap:

$1.98B

Revenue:

$-665.00K

Net Income/Loss:

$-150.11M

P/E Ratio:

-11.79

EPS:

-1.5071

Net Cash Flow:

$-124.53M

1W Performance:

-2.74%

1M Performance:

+32.02%

6M Performance:

+45.54%

1Y Performance:

+140.46%

1-Day Range:

$17.15

$18.34

1-Week Range:

$17.15

$18.61

52-Week Range:

$7.21

$19.15

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name

Amylyx Pharmaceuticals Inc

Sector

Healthcare (1096)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

617-682-0917

Address

55 CAMBRIDGE PARKWAY, CAMBRIDGE

Employee

136

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

AMLX's Discussions on Twitter

Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMLX Amylyx Pharmaceuticals Inc	17.77	1.98B	-665.00K	-150.11M	-124.53M	-1.5071
TAK Takeda Pharmaceutical Co Adr	16.56	52.88B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.76	42.98B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	32.95	38.37B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	75.56	31.68B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	547.06	23.22B	3.17B	1.29B	1.01B	27.09

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-03-26	Initiated	Stifel	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Guggenheim	Buy
Jun-17-25	Initiated	Citigroup	Buy
May-30-25	Initiated	TD Cowen	Buy
Apr-07-25	Upgrade	Mizuho	Neutral → Outperform
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy
Mar-18-24	Downgrade	Mizuho	Buy → Neutral
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Jan-03-24	Initiated	Robert W. Baird	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Jul-24-23	Upgrade	Goldman	Neutral → Buy
Mar-31-23	Initiated	Mizuho	Buy
Jan-05-23	Initiated	BofA Securities	Buy
May-25-22	Initiated	Citigroup	Buy
Apr-01-22	Downgrade	Goldman	Buy → Neutral

View All

Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News

Jul 09, 2026

Amylyx Pharmaceuticals (AMLX) M&A Announcement Summary - Quartr

Jul 09, 2026

Amylyx Pharmaceuticals (AMLX) Proxy filing Summary - Quartr

Jul 09, 2026

Form 144 Amylyx Pharmaceuticals For: 9 July By Investing.com - Investing.com India

Jul 09, 2026

[144] Amylyx Pharmaceuticals, Inc. SEC Filing - Stock Titan

Jul 09, 2026

Jul 08, 2026

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - aol.com

Jul 08, 2026

Amylyx Pharmaceuticals (AMLX) Q3 2024 earnings summary - Quartr

Jul 08, 2026

Jul 07, 2026

Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight - Yahoo Finance

Jul 07, 2026

Jul 04, 2026

AMLXAmylyx Pharmaceuticals Inc Latest SEC Filings - Finviz

Jul 04, 2026

Jul 02, 2026

Companies Like Amylyx Pharmaceuticals (NASDAQ:AMLX) Are In A Position To Invest In Growth - Moomoo

Jul 02, 2026

Jun 30, 2026

Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? - Insider Monkey

Jun 30, 2026

Jun 29, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell 3000E Index - marketscreener.com

Jun 29, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 29, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS: AMLX) dropped from Russell Microcap Index - marketscreener.com

Jun 29, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 3000 Value Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell 2500 Value Benchmark - marketscreener.com

Jun 28, 2026

Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com

Jun 28, 2026

Jun 27, 2026

Enterprise value to EBIT forward of Amylyx Pharmaceuticals, Inc. – NASDAQ:AMLX - TradingView

Jun 27, 2026